[Criteria for suppressive dosage of thyroxine administered in thyroid cancer].
The investigation was concerned with thyroxine therapy for suppression of thyrotrophin synthesis in 1,033 out of 1,544 (66.9%) patients treated for papillary thyroid cancer (hemithyroidectomy--429, thyroidectomy--1,115; 484 of the latter group received radioiodinetherapy postoperatively). Thyroxine 2-5.2 mg/body mass unit was administered for 1-10 yrs (average--4. yrs). Effective daily dose depended on extent of surgery: higher dosage was required after thyroidectomy than hemithyroidectomy, and it was significantly higher after radioiodinetherapy. Bringing thyrotrophin synthesis levels down to normal was necessary in a study based on body mass and height characteristics. Also, an inverse relationship was established between suppressive dose and age. Male patients appeared to require more thyroxine per day than women. Suppressive dosage of thyroxine with regard to age, sex and treatment modality is suggested.
Khmara
I M
IM
Demidchik
Iu E
IuE
Shapet'ko
M N
MN
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D015992:Body Mass Index; D002291:Carcinoma, Papillary / Q000378:metabolism / Q000532:radiotherapy / Q000601:surgery*; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007037:Hypothyroidism / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D012737:Sex Factors; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000532:radiotherapy / Q000601:surgery*; D013965:Thyroidectomy / Q000009:adverse effects* / Q000379:methods; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*; D013974:Thyroxine / Q000008:administration & dosage*; D016896:Treatment Outcome
D013972:Thyrotropin; D013974:Thyroxine